March 25, 2021 -- A new study published in Nature Communications found that intratumoral PVSRIPO therapy through unique activation of antigen-presenting cells in the tumor microenvironment stimulates functional CD8+ T-cell responses, leading to systemic antitumor immunity.
PVSRIPO is an investigational immunotherapy based on the live-attenuated Sabin type 1 poliovirus vaccine developed by Istari Oncology. PVSRIPO has a distinct target (the poliovirus receptor CD155), which is widely expressed in neoplastic cells of most solid tumors.
According to the preclinical data, PVSRIPO triggers sustained type 1/III interferon secretion with minimal release of unwanted cytokines.
The company is preparing to evaluate PVSRIPO in a phase II clinical study to determine its ability to generate a systemic immune response in melanoma tumors and suppress cancer growth.